IL250825A0 - Antibodies against mfi2 and methods of their use - Google Patents

Antibodies against mfi2 and methods of their use

Info

Publication number
IL250825A0
IL250825A0 IL250825A IL25082517A IL250825A0 IL 250825 A0 IL250825 A0 IL 250825A0 IL 250825 A IL250825 A IL 250825A IL 25082517 A IL25082517 A IL 25082517A IL 250825 A0 IL250825 A0 IL 250825A0
Authority
IL
Israel
Prior art keywords
methods
novel anti
mfi2 antibodies
mfi2
antibodies
Prior art date
Application number
IL250825A
Other languages
English (en)
Hebrew (he)
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of IL250825A0 publication Critical patent/IL250825A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
IL250825A 2014-09-05 2017-02-27 Antibodies against mfi2 and methods of their use IL250825A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046610P 2014-09-05 2014-09-05
US201562203836P 2015-08-11 2015-08-11
PCT/US2015/048659 WO2016037119A1 (en) 2014-09-05 2015-09-04 Novel anti-mfi2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
IL250825A0 true IL250825A0 (en) 2017-04-30

Family

ID=55440418

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250825A IL250825A0 (en) 2014-09-05 2017-02-27 Antibodies against mfi2 and methods of their use

Country Status (22)

Country Link
US (1) US10428156B2 (enExample)
EP (1) EP3189079A4 (enExample)
JP (1) JP2017535246A (enExample)
KR (1) KR20170045351A (enExample)
CN (1) CN107001454A (enExample)
AU (1) AU2015311743A1 (enExample)
BR (1) BR112017004444A2 (enExample)
CA (1) CA2959705A1 (enExample)
CL (2) CL2017000506A1 (enExample)
CO (1) CO2017003005A2 (enExample)
CR (1) CR20170117A (enExample)
DO (1) DOP2017000052A (enExample)
EA (1) EA201790529A1 (enExample)
IL (1) IL250825A0 (enExample)
MA (1) MA40612A (enExample)
MX (1) MX2017002862A (enExample)
PE (1) PE20170776A1 (enExample)
PH (1) PH12017500406A1 (enExample)
SG (1) SG11201701650PA (enExample)
TW (1) TW201617368A (enExample)
WO (1) WO2016037119A1 (enExample)
ZA (1) ZA201701674B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
WO2019167874A1 (ja) * 2018-02-27 2019-09-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2020021556A1 (en) * 2018-07-26 2020-01-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions targeting gabra2 and methods for diagnosis and treatment of cancer
CA3124129A1 (en) * 2018-12-21 2020-06-25 Sapreme Technologies B.V. Saponin conjugated to epitope-binding proteins
CN109709340B (zh) * 2018-12-29 2022-02-11 江苏众红生物工程创药研究院有限公司 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
US11617798B2 (en) * 2019-02-05 2023-04-04 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
EP3996747A4 (en) * 2019-07-11 2023-08-16 Tavotek Biotherapeutics (Hong Kong) Limited AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLP) SIGNALING
GB201913594D0 (en) * 2019-09-20 2019-11-06 Univ Birmingham Epigenetic profiling method
US11834512B2 (en) * 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN111909933B (zh) * 2020-06-29 2021-07-02 浙江大学 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用
US20230295330A1 (en) * 2020-08-04 2023-09-21 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
KR20250069943A (ko) * 2022-09-21 2025-05-20 씨젠 인크. Cd228과 결합하는 항체
WO2025025731A1 (zh) * 2023-07-28 2025-02-06 山东博安生物技术股份有限公司 一种适用于免疫组化检测cd228的诊断抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5191066A (en) 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT938320E (pt) 1996-03-26 2010-09-22 Michael S Kopreski Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
AU2559799A (en) 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
CA2341471C (en) 1998-08-27 2009-04-07 Spirogen Limited Pyrrolbenzodiazepines
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
JP4414023B2 (ja) 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
EP1285272A2 (en) 2000-02-08 2003-02-26 University of British Columbia Compositions and methods for screening therapeutic agents
KR20020007432A (ko) 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
EP1256354A1 (en) 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2525243C (en) 2003-05-09 2014-05-27 Transfert Plus Use of melanotransferrin (p97) for regulating plasminogen activation and cell migration
EP1633784B1 (en) 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007504245A (ja) 2003-09-05 2007-03-01 ジェネンテック・インコーポレーテッド 変更したエフェクター機能を有する抗体
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
CA2558195C (en) 2004-03-01 2012-11-06 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
CA2658003A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
PL3207941T6 (pl) 2006-09-07 2020-11-16 Scott & White Memorial Hospital Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US20090130105A1 (en) 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US20090155255A1 (en) 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
EA201290804A1 (ru) 2010-02-21 2013-03-29 БАЙЕР ХелсКер ЛЛСи Способ активации и сопряжения биомолекул
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
KR101772354B1 (ko) * 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
CN106434561A (zh) 2010-09-03 2017-02-22 艾伯维施特姆森特克斯有限责任公司 细胞亚群的鉴定和富集
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
CN103221419B (zh) 2010-09-17 2015-12-09 独立行政法人产业技术综合研究所 肺癌鉴定标志物
WO2012064733A2 (en) 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
US20130259806A1 (en) 2010-12-09 2013-10-03 David Light Dimeric molecular complexes with free cysteine residues and conjugates thereof
BR112013021460B1 (pt) 2011-03-02 2022-12-20 Roche Glycart Ag Anticorpos, composição e uso do anticorpo
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
EP2739649B1 (en) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97 fragments with transfer activity
CA2852594A1 (en) 2011-10-19 2013-04-25 Theratechnologies Inc. Peptide compounds derived from melanotransferrin and uses thereof
KR20110136776A (ko) * 2011-12-12 2011-12-21 경북대학교 산학협력단 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
KR102099073B1 (ko) * 2012-02-24 2020-04-10 애브비 스템센트알엑스 엘엘씨 항 ｓｅｚ6 항체들 및 사용 방법
CN104379602B (zh) * 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
CN107459508A (zh) * 2012-07-20 2017-12-12 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
HRP20190366T1 (hr) 2012-10-12 2019-04-19 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
BR112015018899B1 (pt) 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
CN105431524B (zh) 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 用于降低肿瘤细胞的免疫抑制的方法和组合物
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
JP6713931B2 (ja) 2014-02-11 2020-06-24 シアトル ジェネティクス，インコーポレイティド タンパク質の選択的還元
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use

Also Published As

Publication number Publication date
MA40612A (fr) 2016-03-10
CR20170117A (es) 2017-05-15
KR20170045351A (ko) 2017-04-26
US10428156B2 (en) 2019-10-01
EP3189079A1 (en) 2017-07-12
TW201617368A (zh) 2016-05-16
PH12017500406A1 (en) 2017-07-17
JP2017535246A (ja) 2017-11-30
WO2016037119A1 (en) 2016-03-10
CN107001454A (zh) 2017-08-01
AU2015311743A1 (en) 2017-03-23
MX2017002862A (es) 2017-09-15
CL2017000506A1 (es) 2017-11-03
EP3189079A4 (en) 2018-08-08
ZA201701674B (en) 2019-09-25
BR112017004444A2 (en) 2018-02-27
CL2018001722A1 (es) 2018-10-12
EA201790529A1 (ru) 2017-08-31
SG11201701650PA (en) 2017-04-27
PE20170776A1 (es) 2017-07-04
US20170320960A1 (en) 2017-11-09
DOP2017000052A (es) 2017-04-30
CO2017003005A2 (es) 2017-08-10
CA2959705A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-TREM2 antibodies and methods of using them
IL251868A0 (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
IL257636A (en) Anti-tigit antibodies and methods of use
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
IL248399A0 (en) New anti-43rnf antibodies and methods of use
SG11201706583PA (en) Anti-pvrig antibodies and methods of use
IL259681A (en) New antibodies against claudin and methods of using them
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
IL247754A0 (en) Antibodies against mcam and related methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use